Although IIMM is characterised by the secretion of monoclonal intact immunoglobulins, around 95% of patients have abnormal sFLC concentrations (Table 17.2) [360][361][315][134][363][364][365]. Mead et al. [363] assessed the frequency of sFLC abnormalities at presentation of IIMM according to immunoglobulin isotype. The study comprised 314 patients with IgG MM, 142 with IgA MM, 36 with IgD MM and 5 with IgE MM. Generally, sFLC concentrations were higher in IgA than in IgG patients, but highest in IgD patients (Figures 17.1A and B). Overall, 89% had abnormally high sFLCs, with the following breakdown: IgG 84%, IgA 92%, IgD 94%, and all five of the IgE MM patients. Some patients had normal or reduced concentrations of FLCs, but abnormal κ/λ ratios, indicating monoclonality in association with bone marrow suppression.

Publication Number of patients % of patients with an
abnormal κ/λ sFLC ratio
Mead et al. (2004) [363][366]497 89
Orlowski et al. (2007) [361]487 94
Owen et al. (2007) [364]207 95
Snozek et al. (2008) [365]576 95
Dispenzieri et al. (2008) [360]399 96
Katzmann et al. (2009) [134]467 97
Jeong et al. (2013) [315]159 87

Table 17.2. Summary of studies showing the percentage of IIMM patients with abnormal κ/λ sFLC ratios.

It is noteworthy that the concentration of monoclonal immunoglobulins and monoclonal FLCs are not correlated in IIMM patients (Figure 17.2). However, in the majority of cases, changes in the intact immunoglobulin and the FLC are concordant (Chapter 18). Importantly, discordant responses may indicate the presence of multiple clones, which have been identified by Ayliffe et al. [367][368] in a proportion of MM patients, using dual staining immunocytochemistry. In 82% of MM patients, single populations of cells were present that expressed either intact monoclonal immunoglobulin (with or without monoclonal FLC co-expression [74%]) or monoclonal FLC alone (8%). However, 18% of the samples contained a mixture of both cell populations [367]. Therefore, measurement of both monoclonal intact immunoglobulins and sFLCs in IIMM patients provides information on the underlying tumour cell clones, which may evolve differentially over the course of the disease (Chapter 19).